In order to assess visfatin’s relationship with disease outcomes, treatment response, and tumor burden and to determine any treatment-related effects, future studies should include longitudinal measurements or compare treatment-naive patients with those undergoing therapy. The gene discussed is NAMPT; the disease is neoplasm.